APC8015 and Bevacizumab in Treating Patients With Prostate Cancer

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

Phase II trial to study the effectiveness of APC8015 combined with bevacizumab in treating patients who have undergone radiation therapy and/or surgery and who have progressive prostate cancer. Biological therapies such as APC8015 use different ways to stimulate the immune system and stop cancer cells from growing. Monoclonal antibodies such as bevacizumab can locate tumor cells and kill them without harming normal cells. Combining monoclonal antibody therapy with biological therapy may kill more cancer cells.

Key facts

Study ID

NCT00027599

Run by

National Cancer Institute (NCI)

People needed

25

Starts

2001-12-01

Last updated by the study team

2013-02-11

Who can join

Age: any. Sex: male. Healthy volunteers: not accepted.

Where it is running

• UCSF Comprehensive Cancer Center — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.